New Anti-Inflammation drug tested for kidney patients in china
NCT ID NCT05379829
Summary
This study tested how the experimental drug ziltivekimab behaves in the body of Chinese adults who have chronic kidney disease along with signs of body-wide inflammation. Twenty-four participants received either the active drug or a placebo dummy injection three times over six months. Researchers measured drug levels in the blood and checked for safety to see if it could help control inflammation linked to kidney disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE AND SYSTEMIC INFLAMMATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
-
Chinses People's Liberation Army General Hospital-Nephrology
Beijing, Beijing Municipality, 100853, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
The First Affiliated Hospital Of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Soochow University-Endocrinology
Suzhou, Jiangsu, 215006, China
-
Zhongda Hospital Southeast University-Nephrology
Nanjing, Jiangsu, 210009, China
-
Zhongda Hospital Southeast University-Neurology
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.